Literature DB >> 15353354

Transglutaminase contributes to CPPD crystal formation in osteoarthritis.

David Heinkel1, Claudia M Gohr, Miwa Uzuki, Ann K Rosenthal.   

Abstract

Calcium pyrophosphate dihydrate (CPPD) crystals are common components of osteoarthritic joints and correlate with a poor prognosis. Transglutaminase (Tgase) enzymes have been implicated in pathologic mineralization in cartilage; yet, definitive studies linking Tgase activity to CPPD crystal formation in osteoarthritic articular cartilage are lacking. We measured in-vivo Tgase activity in osteoarthritic and normal human cartilage, and explored the effect of Tgase inhibitors on CPPD crystal formation by normal chondrocytes. Osteoarthritic articular cartilage from was obtained from specimens discarded at the time of knee replacement surgery. Normal adult cartilage samples from a tissue bank were used as controls. Tgase-specific isopeptide (epsilon-(gamma-glutamyl) lysine) bonds were measured in cartilage extracts by HPLC. Tgase-specific crosslinks were localized in osteoarthritic cartilage by immunohistochemistry. The effect of Tgase inhibition was determined in an in-vitro model of CPPD crystal formation. Tgase-specific crosslink levels were 1.55 +/- 0.3 picomoles/ng protein in normal human adult articular cartilage and 4.74 +/- 0.7 picomoles/ng protein in osteoarthritic human cartilage (p less than 0.001). Immunostaining confirmed the presence of Tgase crosslinks in the pericellular matrix of chondrocytes at potential sites of CPPD crystal formation. Tgase inhibitors suppressed CPPD crystal formation by porcine chondrocytes. These findings support a role for Tgase in CPPD crystal formation in aging or degenerated cartilage.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15353354     DOI: 10.2741/1477

Source DB:  PubMed          Journal:  Front Biosci        ISSN: 1093-4715


  9 in total

Review 1.  Pathophysiology of articular chondrocalcinosis--role of ANKH.

Authors:  Abhishek Abhishek; Michael Doherty
Journal:  Nat Rev Rheumatol       Date:  2010-11-23       Impact factor: 20.543

2.  Osteopontin promotes pathologic mineralization in articular cartilage.

Authors:  Ann K Rosenthal; Claudia M Gohr; Miwa Uzuki; Ikuko Masuda
Journal:  Matrix Biol       Date:  2006-10-20       Impact factor: 11.583

3.  Point: Hydroxyapatite crystal deposition is intimately involved in the pathogenesis and progression of human osteoarthritis.

Authors:  Geraldine M McCarthy; Herman S Cheung
Journal:  Curr Rheumatol Rep       Date:  2009-04       Impact factor: 4.592

4.  Calcium deposition in osteoarthritic meniscus and meniscal cell culture.

Authors:  Yubo Sun; David R Mauerhan; Patrick R Honeycutt; Jeffrey S Kneisl; H James Norton; Natalia Zinchenko; Edward N Hanley; Helen E Gruber
Journal:  Arthritis Res Ther       Date:  2010-03-30       Impact factor: 5.156

5.  Type II collagen levels correlate with mineralization by articular cartilage vesicles.

Authors:  Brian Jubeck; Emily Muth; Claudia M Gohr; Ann K Rosenthal
Journal:  Arthritis Rheum       Date:  2009-09

6.  Dexamethasone promotes calcium pyrophosphate dihydrate crystal formation by articular chondrocytes.

Authors:  Mark Fahey; Elizabeth Mitton; Emily Muth; Ann K Rosenthal
Journal:  J Rheumatol       Date:  2009-01       Impact factor: 4.666

7.  Transglutaminase 2 is a marker of chondrocyte hypertrophy and osteoarthritis severity in the Hartley guinea pig model of knee OA.

Authors:  J L Huebner; K A Johnson; V B Kraus; R A Terkeltaub
Journal:  Osteoarthritis Cartilage       Date:  2009-03-24       Impact factor: 6.576

8.  Advanced glycation end products increase transglutaminase activity in primary porcine tenocytes.

Authors:  Ann K Rosenthal; Claudia M Gohr; Elizabeth Mitton; Vincent Monnier; Todd Burner
Journal:  J Investig Med       Date:  2009-02       Impact factor: 2.895

9.  Histone Deacetylase Inhibitors Downregulate Calcium Pyrophosphate Crystal Formation in Human Articular Chondrocytes.

Authors:  Chi-Ching Chang; Kun-Lin Lee; Tze-Sian Chan; Chia-Chen Chung; Yu-Chih Liang
Journal:  Int J Mol Sci       Date:  2022-02-26       Impact factor: 5.923

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.